NEXT GENERATION THERAPIES
Charles L. Raison, M.D., of the University of Arizona, will conduct a trial of whole body hyperthermiaraising the body temperatureto treat depression. A preliminary trial showed rapid, lasting improvement after a single session. Animal research suggests hyperthermia affects a neural pathway from the skin to specific brain cells. The research will try to confirm whole body hyperthermia as a safe, fast-acting new antidepressant and evaluate the relevance of peripheral neural pathways.
Jonathan P. Roiser, Ph.D., of the University of London, will examine the neural mechanisms affected by transcranial direct current stimulation (tDCS), a brain stimulation treatment for depression, and its ability to boost the effectiveness of cognitive behavioral psychotherapy. Treatment with tDCS stimulates the left dorsolateral prefrontal cortex region of the brain, which is involved in higher cognitive functions.
Gabrielle Rudenko, Ph.D., of the University of Michigan, will explore a protein, known to regulate the expression of specific genes in brain reward pathways, as a target for treatment of intractable depression. In normal responses to stress, the targeted protein accumulates in specific brain regions and spurs resilience mechanisms. Levels appear dramatically reduced in postmortem brain tissue of depressed patients. By clarifying its mechanisms and function, Dr. Rudenko hopes to exploit its natural antidepressant
|Contact: Sally Corbett|
Brain & Behavior Research Foundation